CD274 and neoplasm: Supported by the findings of the phase III Keynote 048 clinical trial, pembrolizumab has been gained approval from both the EMA and FDA in the first‐line setting for either monotherapy or combination therapy with chemotherapy depending on the status of tumor expression of programmed cell death protein ligand‐1 (PD‐L1).